HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
HSBC adjusted ratings for biopharma stocks, citing high multiples and the need for stock-specific catalysts. Novartis was upgraded to Hold with a target price of 110 CHF, while Amgen was downgraded to Hold with a target of $425. AbbVie and Bayer were kept as Buy with raised targets. The changes reflect expectations for upcoming clinical trials and legal outcomes.
How this was made
The 30-second read
Why it matters
The rating adjustments reflect a shift toward bottom‑up stock selection, highlighting specific companies with perceived upside or downside.
Market read
Analyst rating changes can move individual stocks and influence sector sentiment, especially in biotech.
What to watch
Potential macro‑economic headwinds and currency fluctuations could dampen the impact of target changes.
Background
HSBC released a biopharma catalyst review, adjusting ratings and price targets across its coverage universe.
Ticker impact
HSBC upgraded Novartis to Hold and raised its target price to 110 CHF.
Modest price appreciation over the next weeks.
Rating upgrade and higher target suggest improved outlook despite recent trial failures.
HSBC downgraded Amgen to Hold and cut its target price to $425.
Potential short‑term decline.
Target cut reflects weaker growth expectations tied to upcoming obesity trial.
HSBC retained Buy on AbbVie and raised its target price to $315.
Possible modest rally.
Target raise reflects confidence in pipeline readouts for Skyrizi and Rinvoq.
Market effects
Biopharma sector may see re‑rating as analysts adjust for trial risk and litigation outcomes.
European‑listed pharma stocks could experience modest volatility.
Rating changes may influence global biotech ETFs and fund allocations.
Counterpoint
Investors might view the upgrades as premature given recent trial failures and pending litigation.
Key entities
- AnalystHSBC
Global bank providing the rating changes.
